Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy
Yuna Lee, Sun Young Kyung, Soo Jin Choi, Soo-Mee Bang, Seong Hwan Jeong, Dong Bok Shin, Jae Hoon Lee
Korean J Intern Med. 2006;21(3):183-186. Published online September 30, 2006
Rituximab, a chimeric monoclonal antibody directed against CD20, has become a part of the standard therapy for patients with non-Hodgkin's lymphoma either in combination with other drugs or as a single agent. The CD20 antigen is expressed on 95% of B-cell lymphoma cells and normal B-cells but, is..
|